Kinsenoside alleviates MPTP-induced Parkinson’s disease via Akt activation and apoptosis inhibition in a mouse model
Behavioural Brain Research · 2026-09 · 513 · 116314
DOI: 10.1016/j.bbr.2026.116314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Behavioural Brain Research, 2026-09. Verfasst von Tsung-Ming Yeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: General Research Service Center, National Pingtung University of Science and Technology, Pingtung, Taiwan. Hauptthemen laut MEDLINE: 4-Butyrolactone, Apoptosis, Proto-Oncogene Proteins c-akt, Neuroprotective Agents. Die Arbeit nennt 61 Literaturangaben. Gefördert von: National Pingtung University of Science and Technology.
Abstract (Originalsprache)
Parkinson's disease (PD) is a common neurodegenerative disorder primarily characterized by motor dysfunction; however, recent studies have highlighted a broad spectrum of non-motor symptoms, including cognitive impairment and psychological harm. While dopaminergic drugs effectively manage motor symptoms in the early stages, efficacy often declines, and symptoms may worsen as the disease progresses. Kinsenoside, the primary bioactive compound from Anoectochilus formosanus, exhibits diverse pharmacological effects, yet its potential in treating PD remains unexplored. This study evaluated whether Kinsenoside could alleviate PD symptoms in a mouse model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behavioral results demonstrated that Kinsenoside significantly attenuated bradykinesia in the pole test, reduced motor deficits in the traction test, and enhanced long-term cognitive memory in the passive avoidance test. Furthermore, Kinsenoside treatment significantly restored dopamine (DA) levels and increased tyrosine hydroxylase (TH) expression in the substantia nigra of PD mice. Mechanistically, Kinsenoside activated the Akt signaling pathway and decreased the protein expression ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2), thereby inhibiting neuronal apoptosis. These findings suggest that Kinsenoside exerts potent neuroprotective effects and represents a promising therapeutic candidate for alleviating both motor and non-motor symptoms associated with Parkinson's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Research Service Center, National Pingtung University of Science and Technology, Pingtung, Taiwan.
- Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung, Taiwan.
- Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung, Taiwan. Electronic address: wlshih@mail.npust.edu.tw.
Förderung
- National Pingtung University of Science and Technology
Zitieren
APA
Yeh, T. M., Sung, W. W., Li, M. Z., Chang, C. I., & Shih, W. L. (2026). Kinsenoside alleviates MPTP-induced Parkinson’s disease via Akt activation and apoptosis inhibition in a mouse model. Behavioural Brain Research, 513, 116314. https://doi.org/10.1016/j.bbr.2026.116314
Vancouver
Yeh TM, Sung WW, Li MZ, Chang CI, Shih WL. Kinsenoside alleviates MPTP-induced Parkinson’s disease via Akt activation and apoptosis inhibition in a mouse model. Behavioural Brain Research. 2026;513:116314. doi:10.1016/j.bbr.2026.116314
BibTeX
@article{Yeh2026,
author = {Yeh, Tsung-Ming and Sung, Wei-Wen and Li, Ming-Zhe and Chang, Chih-I and Shih, Wen-Ling},
title = {Kinsenoside alleviates MPTP-induced Parkinson’s disease via Akt activation and apoptosis inhibition in a mouse model},
journal = {Behavioural Brain Research},
year = {2026},
volume = {513},
pages = {116314},
doi = {10.1016/j.bbr.2026.116314}
}
EUVIMED